NataliyaVUbohaMDPhD

Oncology • Madison, WI

Hematologic Oncology

Physician

Join to view full profile

Dr. Uboha is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Uboha's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-266-6020
Is this information wrong?

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Yale-New Haven Medical CenterResidency, Internal Medicine, 2007 - 2010
Yale School of MedicineClass of 2007

Certifications & Licensure

WI State Medical License 2015 - 2025
CT State Medical License 2010 - 2015
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs Start of enrollment: 2017 Aug 22
Terminated
Phase 1
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer Start of enrollment: 2018 May 29
Active, not recruiting
Phase 1, Phase 2
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 Start of enrollment: 2019 Aug 26
Terminated
Phase 2
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma Start of enrollment: 2020 Jul 13
Recruiting
Phase 2
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Start of enrollment: 2020 May 26
Recruiting
Phase 3
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Start of enrollment: 2020 Mar 01
Active, not recruiting
Phase 3
Roles: Contact
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Start of enrollment: 2024 Mar 08
Recruiting
Phase 2
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Precision of liver and pancreas apparent diffusion coefficients using motion-compensated gradient waveforms in DWI.
Jitka Starekova, Ruiqi Geng, Zihan Wang, Yuxin Zhang, Diego Hernando, Nataliya V Uboha, Ali Pirasteh> ;Magnetic Resonance Imaging. 2024 Apr 17
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Rona Yaeger, Nataliya V Uboha, Meredith S Pelster, Tanios S Bekaii-Saab, Minal Barve, Joel Saltzman, Joshua K Sabari, Julio A Peguero, Andrew Scott Paulson, Pasi A Jän...> ;Cancer Discovery. 2024 Apr 8
Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2.
Eric Mehlhaff, Devon Miller, Johnathan E Ebben, Oleksii Dobrzhanskyi, Nataliya V Uboha> ;Hematology/oncology Clinics of North America. 2024 Mar 13
Current and Future Biomarkers in Esophagogastric Adenocarcinoma.
Ebben, J., Sappenfield, R., Mehlhaff, E., Miller, D., Uboha, N.> ;Journal of Gastrointestinal Cancer. 2024 Jan 27
Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression.
Xingchen Dong, Ming Qi, Chunmiao Cai, Yu Zhu, Yuwenbin Li, Sally Coulter, Fei Sun, Christopher Liddle, Nataliya V Uboha, Richard Halberg, Wei Xu, Paul Marker, Ting Fu> ;JCI Insight. 2024 Jan 23
Treatment of Oligometastatic GI Cancers.
Basree, M., Basree, M., Basree, M., Marcinak, C., Schwartz, P., Basree, M., Hurst, N., Bassetti, M., Kratz, J., Uboha, N.> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2024 Jan 1
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward Kim, Stacey Stein, ...> ;British Journal of Cancer. 2024 Feb 1
Esophageal carcinoma with SMARCA4 mutation: Unique diagnostic challenges.
Min Cui, Kayla Lemmon, Zhicheng Jin, Nataliya V Uboha> ;Pathology, Research and Practice. 2023 Aug 1
Undifferentiated Carcinoma of Esophagus with SMARCA4 Deletion Expressing Synaptophysin: A Potential Diagnostic Pitfall.
Min Cui, Nataliya Uboha> ;International Journal of Surgical Pathology. 2024 Apr 1
32 citations
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Manish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, Thierry Alcindor, Angela N Bartley, Aubrey Belk Malowany, Nishin A Bhadkamkar, Dana C Deighton, Yelena Janjigian...> ;Journal of Clinical Oncology. 2023 Mar 1
3 citations
Motion-robust, blood-suppressed, reduced-distortion diffusion MRI of the liver.
Ruiqi Geng, Yuxin Zhang, James Rice, Matthias R Muehler, Jitka Starekova, David R Rutkowski, Nataliya V Uboha, Ali Pirasteh, Alejandro Roldán-Alzate, Arnaud Guidon, Di...> ;Magnetic Resonance in Medicine. 2023 Mar 1
18 citations
Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.
Monica A Patel, Jeremy D Kratz, Sam J Lubner, Noelle K Loconte, Nataliya V Uboha> ;Journal of Clinical Oncology. 2022 Aug 20
2 citations
AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma.
Monica Patel, Nataliya Uboha> ;JAMA Oncology. 2022 Aug 1
7 citations
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
Steven B Maron, Stephanie Moya, Federica Morano, Matthew J Emmett, Joanne F Chou, Shalom Sabwa, Henry Walch, Bryan Peterson, Alexa B Schrock, Liangliang Zhang, Yelena ...> ;Journal of Clinical Oncology. 2022 Aug 1
15 citations
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako...> ;Clinical Cancer Research. 2022 May 13
90 citations
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(...
Jonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, Katrina Z Kao, Ana Lako, Junko Tsuji, Yang Liu, Ryan C Brennick, Ryan D Gentzler, Carrie Lee, Joleen H...> ;The Lancet. Oncology. 2022 Feb 1
7 citations
Treatment Approach to Adenocarcinoma of the Ampulla of Vater.
Monica Patel, Nataliya Volodymyrivna Uboha> ;Current Treatment Options in Oncology. 2021 Sep 29
13 citations
Microwave ablation for colorectal cancer metastasis to the liver: a single-center retrospective analysis.
Emily A. Knott, Timothy J. Ziemlewicz, Sam J. Lubner, John F. Swietlik, Sharon M. Weber, Annie M. Zlevor, Colin Longhurst, J. Louis Hinshaw, Meghan G. Lubner, Daniel M...> ;Journal of Gastrointestinal Oncology. 2021 Aug 1
222 citations
Neuroendocrine and adrenal tumors, version 2.2021
Manisha H. Shah, Whitney S. Goldner, Al B. Benson, Emily K. Bergsland, Lawrence S. Blaszkowsky, Pamela Brock, Jennifer A. Chan, Satya Das, Paxton V. Dickson, Paul T. F...> ;Journal of the National Comprehensive Cancer Network. 2021 Jul 28
22 citations
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Aung Naing, Fiona C Thistlethwaite, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Patrick A. Ott, Patricia LoRusso, Javier Garcia-Corbacho, Valentina B...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
5 citations
A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer.
Michael Cecchini, Jeremy S. Kortmansky, Can Cui, Wei Wei, Jaykumar R. Thumar, Nataliya Volodymyrivna Uboha, Navid Hafez, Jill Lacy, Neal A. Fischbach, Kert D. Sabbath,...> ;Cancer. 2020 Dec 22
24 citations
Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma.
Purabi Dhakras, Nataliya Uboha, Vanessa L. Horner, Erica Reinig, Kristina A. Matkowskyj> ;Translational Gastroenterology and Hepatology. 2020 Oct 5
5 citations
A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer.
Jacob S. Witt, Aleksandra Kuczmarska-Haas, Meghan G. Lubner, Scott B. Reeder, Steve Y. Cho, Rebecca M. Minter, Sharon M. Weber, Sean Ronnekleiv-Kelly, Daniel E. Abbott...> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Sep 14
4 citations
Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.
Nataliya Volodymyrivna Uboha, Sam J. Lubner, Noelle K. LoConte, Daniel Mulkerin, Jens C. Eickhoff, Dustin A. Deming> ;Investigational New Drugs. 2020 Apr 6
Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resect...
Patrick B. Schwartz, Nataliya Volodymyrivna Uboha, Sharon M. Weber> ;Annals of Surgical Oncology. 2019 Aug 22
Join now to see all

Lectures

Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Resea...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020

Press Mentions

Chemotherapy-Immunotherapy Combination Shows Efficacy in Esophagogastric Cancer SubsetJuly 12th, 2022
Adding Opdivo in First-Line Shows Promise in HER2+ Esophagogastric CancerJune 23rd, 2022
Patient with Rare Cancer Uses Telehealth to Access Clinical TrialMay 20th, 2021
Join now to see all